April 2, 2012
Novartis Pharma announced on March 30 that it filed on the same day for an additional indication of diabetic macular edema (DME) for its age-related macular degeneration (AMD) treatment Lucentis Intravitreal Injection 2.3 mg/0.23 mL (ranibizumab (recombinant)). Lucentis is a...read more